- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 08.12.25 | Terns drug shows potential to challenge Novartis' blockbuster leukemia treatment | ||
| 08.12.25 | Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay | ||
| 08.12.25 | Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar | ||
| 08.12.25 | How digital companion apps unlock value across the drug lifecycle | ||
| 08.12.25 | At ASH, Lilly makes case to widen Jaypirca use in leukemia, lymphoma | ||
| 05.12.25 | RFK Jr.'s hand-picked panel questions childhood vaccine schedule | ||
| 05.12.25 | Hemophilia gene therapies are struggling on the market, even as innovation soars | ||
| 05.12.25 | Praxis soars higher; Bristol Myers' CAR-T therapy wins broader use | ||
| 04.12.25 | CDC panel again postpones vote on newborns' hepatitis B shot | ||
| 04.12.25 | An Arch-backed biotech raises $53M to fight neurodegeneration | ||
| 04.12.25 | 12 former FDA chiefs blast Prasad's move to toughen vaccine standards | ||
| 04.12.25 | Tracey Beth Høeg, top Makary deputy, named head of FDA drug office | ||
| 04.12.25 | UniQure slides further on outlook for Huntington's gene therapy | ||
| 03.12.25 | After finding 'irregularities,' Bristol Myers to extend key trial of Cobenfy in Alzheimer's psychosis | ||
| 03.12.25 | Capricor soars on positive results for Duchenne cell therapy | ||
| 03.12.25 | Pharvaris' pill succeeds in late-stage trial for rare swelling disorder | ||
| 02.12.25 | Richard Pazdur, FDA drug czar, to retire from agency | ||
| 02.12.25 | FDA details plan to scale back animal tests for some antibody drugs | ||
| 02.12.25 | Janux sinks on 'overreaction' to prostate cancer data; RFK Jr. replaces ACIP chair | ||
| 02.12.25 | The 'clever' tool increasingly getting bigger biotech deals signed | ||
| 01.12.25 | UK agrees to boost drug prices to dodge US pharma tariffs | ||
| 01.12.25 | Regeneron inks gene editing deal with startup Tessera | ||
| 01.12.25 | Belite continues ascent as Stargardt drug hits mark in late-stage trial | ||
| 01.12.25 | With $130M, Protego pushes forward a new type of amyloidosis drug | ||
| 01.12.25 | From feedstocks to infrastructure, Indiana's bioeconomy is on the move |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .